ΔNp63α promotes Bortezomib resistance via the CYGB–ROS axis in head and neck squamous cell carcinoma

Bortezomib, a proteasome inhibitor, proved potent in the treatment of recurrent multiple myeloma or mantle cell lymphoma. However, slow progress was made when it was applied to treat solid tumors. We discovered that different head and neck squamous cell carcinoma (HNSCC) cell lines had significantly...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Peng, Zhang, Caiyun, Song, Xianmin, Zhang, Dadong, Zhu, Minhui, Zheng, Hongliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994767/
https://www.ncbi.nlm.nih.gov/pubmed/35397613
http://dx.doi.org/10.1038/s41419-022-04790-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994767/
https://www.ncbi.nlm.nih.gov/pubmed/35397613
http://dx.doi.org/10.1038/s41419-022-04790-0

Ejemplares similares